beta Amyloid Monoclonal Antibody (BAM01 (6F/3D)), Invitrogen™

Mouse Monoclonal Antibody

Brand:  Invitrogen MA511617

Product Code. 11364483

Description

MA5-11617 targets Amyloid Beta in IHC (P) applications and shows reactivity with Human samples. The MA5-11617 immunogen is a synthetic peptide consisting of residues 8-17 (SGYEVHHQKL) of the amyloid beta-protein/amyloid A4 which is the same as aa 660-669 of human amyloid A4 / amyloid Beta protein precursor.

Amyloid beta peptide (Abeta/Beta-amyloid) is the major constituent of amyloid plaques in the brains of individuals afflicted with Alzheimer's disease. Abeta peptide is 40-43 amino acids long and generated from the beta-amyloid precursor protein (beta APP) in a two-step process. The first step involves cleavage of the extracellular, amino-terminal domain of beta APP. Protein cleavage is performed by an aspartyl protease, beta-secretase (BACE) which is synthesized as a propeptide and must be modified to the mature and active form by the prohormone convertase, furin. Beta APP cleavage by the mature form of BACE results in the cellular secretion of a segment of beta APP, and a membrane-bound remnant. The remnant protein is processed by another protease, gamma-secretase. Gamma-secretase cleaves an intra-membrane site in the carboxyl-terminal domain of beta APP, thus generating the amyloid beta peptide. Gamma-secretase is believed to be a multi-subunit complex containing presenilin-1 and 2 as central components. The transmembrane glycoprotein, nicastrin, is associated with presinilins and has been found to bind to the carboxyl-terminus of beta APP and helps to modulate the production of the amyloid beta peptide. Abeta is an extracellular filamentous protein component of amyloid cores, neuritic plaques and is also found as a deposit in neurofibrillary tangles. Alzheimer’s disease, the most common cause of senile dementia, is characterized by abnormal filamentous protein deposits in the brain. Beta amyloid deposits are also detected in Lewy body dementia, Down’s syndrome, amyloidosis (Dutch type), cerebroarterial amyloidosis (cerebral amyloid angiopathy) and in the Guam Parkinson-Dementia complex.

Specifications

• Antigen: beta Amyloid
• Classification: Monoclonal
• Concentration: Conc. Not Determined
• Formulation: tissue culture supernatant with 0.09% sodium azide
• Gene Accession No.: P05067
• Gene Symbols: APP
• Immunogen: A synthetic peptide consisting of residues 8-17 (SGYEVHHQKL) of the amyloid beta-protein/amyloid A4 which is the same as aa 660-669 of human amyloid A4 / amyloid Beta protein precursor
• Regulatory Status: RUO
• Gene ID (Entrez): 351
• Content And Storage: 4° C
• Form: Liquid

• Applications: Immunohistochemistry (Paraffin)
• Clone: BAM01 (6F/3D)
• Conjugate: Unconjugated
• Gene: APP
• Gene Alias: A4; AAA; ABETA; Abeta40; Abeta42; ABPP; AD1; Adap; AG; AICD-50; AICD-57; AICD-59; AID(50); AID(57); AID(59); Alpha-CTF; Alpha-secretase C-terminal fragment; Alzheimer disease; Alzheimer disease amyloid A4 protein homolog; alzheimer disease amyloid protein; Amyloid; amyloid A4; Amyloid b; Amyloid beta; amyloid beta (A4) precursor protein; amyloid beta (A4) precursor protein (peptidase nexin-II, Alzheimer disease); amyloid beta A4 protein; amyloid beta precursor protein; Amyloid intracellular domain 50; Amyloid intracellular domain 57; Amyloid intracellular domain 59; Amyloid precursor protein; amyloid precursor protein variant 1; amyloid precursor protein variant 2; Amyloid β; amyloid-beta A4 protein; amyloid-beta A4 protein; amyloid beta A4 protein; Amyloid-beta precursor protein; Amyloid-beta protein 40; Amyloid-beta protein 42; Amyloidogenic glycoprotein; APP; APP-C57; APP-C59; APP-C99; APPI; appican; beta amyloid protein; beta amyloid protein precursor; beta-amyloid peptide; be
• Host Species: Mouse
• Quantity: 500 μL
• Primary or Secondary: Primary
• Target Species: Human
• Product Type: Antibody
• Isotype: IgG1 κ